CELADON PHARMACEUTICALS PLC Logo

CELADON PHARMACEUTICALS PLC

Vertically integrated pharma developing cannabis medicines for chronic pain.

CEL | IL

Overview

Corporate Details

ISIN(s):
GB00BDQYGP38
LEI:
213800YXCATORT475807
Country:
United Kingdom
Address:
32-33 COWCROSS STREET, EC1M 6DF LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and commercial sale of cannabis-based medicines. The company's primary target market is chronic pain, aiming to provide alternatives to traditional treatments. It operates a licensed, 100,000 sq ft, EU-GMP certified facility for the indoor cultivation of high-THC cannabis and the extraction of Active Pharmaceutical Ingredients (API). A key differentiator is its MHRA-conditionally approved clinical trial for chronic pain, which seeks to generate robust data for potential reimbursement by national health services. Founded in 2018, Celadon is also engaged in R&D to generate novel intellectual property and develop a pipeline of prescription medicines for various conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-28 17:10
Post-Annual General Meeting Information
Result of General Meeting
English 20.4 KB
2025-07-02 08:00
Pre-Annual General Meeting Information
Proposed Cancellation
English 99.3 KB
2025-07-01 12:48
Capital/Financing Update
Funding Update
English 10.8 KB
2025-07-01 09:20
Post-Annual General Meeting Information
Result of AGM
English 24.0 KB
2025-06-30 08:00
Report Publication Announcement
Funding and Operational Update, Delay in Results
English 22.5 KB
2025-06-11 08:00
Capital/Financing Update
New Committed Credit Facility
English 14.2 KB
2025-06-06 16:55
Regulatory News Service
Funding Update, Notice of AGM
English 12.1 KB
2025-05-30 19:07
Capital/Financing Update
Funding Update
English 11.3 KB
2025-03-19 08:00
Capital/Financing Update
Funding Update
English 11.8 KB
2025-02-26 14:00
Capital/Financing Update
New Committed Credit Facility
English 15.5 KB
2025-02-12 08:00
Capital/Financing Update
Finance Update
English 10.4 KB
2025-01-31 08:00
Capital/Financing Update
Finance Update
English 10.7 KB
2025-01-16 08:00
Regulatory News Service
Update on Strategic Collaboration
English 13.7 KB
2025-01-02 08:00
Capital/Financing Update
Funding Update
English 10.6 KB
2024-12-20 08:00
Capital/Financing Update
Finance Update
English 10.8 KB

Automate Your Workflow. Get a real-time feed of all CELADON PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CELADON PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884

Talk to a Data Expert

Have a question? We'll get back to you promptly.